Orexin A in adolescents with anxiety disorders

Basit Öğe Kaydı
dc.contributor.authorAkca, Omer Faruk
dc.contributor.authorUzun, Necati
dc.contributor.authorKilinc, Ibrahim
dc.date.accessioned2024-02-23T14:20:33Z
dc.date.available2024-02-23T14:20:33Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjectives: The relationships between orexins and stress-related conditions have been well documented in animal studies. However, human studies confirming this relationship are limited. The aim of this study was to investigate the association between orexin-A and anxiety disorders in adolescents. Additionally, we aimed to examine the relationship between orexin-A and cortisol levels in those with anxiety disorders. Methods: A total of 56 medication-free adolescents diagnosed with any anxiety disorder, except for specific phobias, and 32 healthy controls were included in this study. Depression, state and trait anxiety levels of the participants were measured using self-report scales. Orexin-A and cortisol levels were measured by an enzyme-linked immunosorbent assay (ELISA). Results: Analysis of covariance (ANCOVA) indicated that serum orexin-A levels were significantly higher in the anxiety disorder group than in the control group while controlling for age, sex and depression levels. After controlling for age and sex, orexin-A levels were positively and negatively correlated to depression and cortisol levels, respectively. In addition, a positive correlation trend between trait anxiety and orexin-A was found. Conclusions: Orexin-A levels are higher in adolescents with anxiety disorder; however, depressive symptoms should be considered when investigating this relationship.en_US
dc.description.sponsorshipScientific Research Project Coordination Unit of Necmettin Erbakan University [181218008]en_US
dc.description.sponsorshipFunding for this study was provided by a grant from the Scientific Research Project Coordination Unit of Necmettin Erbakan University (Project no. 181218008).en_US
dc.identifier.doi10.1080/13651501.2019.1711425
dc.identifier.endpage134en_US
dc.identifier.issn1365-1501
dc.identifier.issn1471-1788
dc.identifier.issue2en_US
dc.identifier.pmid31913740en_US
dc.identifier.scopus2-s2.0-85078602703en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage127en_US
dc.identifier.urihttps://doi.org/10.1080/13651501.2019.1711425
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13209
dc.identifier.volume24en_US
dc.identifier.wosWOS:000506284900001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofInternational Journal Of Psychiatry In Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnxiety Disordersen_US
dc.subjectDepressionen_US
dc.subjectOrexinen_US
dc.subjectCortisolen_US
dc.subjectAdolescenten_US
dc.titleOrexin A in adolescents with anxiety disordersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu